News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

US Department of Health and Human Services Grants Orphan Drug Status to BioCancell Therapeutics's Ovarian Cancer Drug


8/24/2009 10:57:06 AM

TEL AVIV, Israel--(BUSINESS WIRE)--Tikcro Technologies (PK: TIKRF) today announced that the United States (“US”) Department of Health and Human Services ("HHS") has granted orphan drug status to BioCancell's BC-819 drug, currently in Phase I/IIa clinical trials, for its use in treating ovarian cancer.

Read at BioSpace.com

Related News

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES